Click on image for lager view.
THE DEVICE WITH NUCLEAR TRANSMUTATIONAL BIOENERGY
NON - INVASIVE ELECTROINSERTION IN VIVO
IMPROVES: METABOLISM, ANABOLISM, DRUG DELIVERY,TRANSMEMBRANE ACTION, CELLULAR ACTIVITY
WORLD'S STRONGEST PULSED ELECTROMAGNETIC FIELD (PMF)
PAP ELECTRODYNAMICS - Bioenergy Delivery Systems
THE SPARK OF LIFE
Ion Magnetic Induction Therapy
BACKGROUND
The PAP Ion Magnetic Induction (IMI), an investigational medical device in the U.S, is a proprietary invention of Professor Panos T. Pappas, now at the Piraeus Technical University in Greece. In 1984 he began working with a colleague on a high-current research project in the laboratories of the Massachusetts Institute of Technology. They were assisted by his then pregnant wife.
His colleague and close friend was diagnosed with an inoperable cancer with less than three month survival prognosis, but continued to work on the plasma physics project which involved repeated daily, electrical arcing that occurred with the sudden opening of massively high-current circuits in the catastrophic heat failure of various conductors.
After finishing th.e project and returning to Greece, Professor Pappas was astonished to learn that at last examination his friend's cancer had entirely disappeared without a trace. In discussing this phenomenon, they considered that exposure to repeated arcing may have caused this remission. Alarmed at the possibility that the biological effects of such exposure may have had adverse effects on his still-unborn son, Pappas immediately launched an investigation by subjecting rats to the same type of high-current fields.
Fortunately, Mrs. Pappas bore a normal, healthy son. However, in continuing his animal studies, he found that tumors implanted in laboratory animals cQnsistentlV shrank and disappeared when exposed to the electromagnetic field pulses of the device he had built for that purpose. In view of a long series of successful animal trials, and as no adverse effects were noted in either the experimental animals or controls, Pappas off ered his IMI device for the experimental treatment of human cancer patients at the Papanikolaou Oncology Research Center of the Hellenic Anticancer Institute.
The first of these was perhaps the most dramatic example of what was to follow. In 1990 the patient presented in extremis with stage IVa uterine cancer, vaginal fistula, lymphonodes and severe abdominal hemorrhage, and was not expected to survive. With no other therapy than six months of treatments with the prototype IMI (which has since been greatly improved), she became the only patient in her hospital's records with similar complaints that was discharged in a cured and healthy state.
In continuing to treat more patients, many of whom had other medical problems, some surprising new discoveries began to emerge. In one such patient, the ugly, painful, swollen knuckles of rheumatoid arthritis were visibly reduced in size auring a single treatment and the pain disappearea. In another patient with a detached retina in one eye, the retina reartachea spontaneously without any other treatment. Open wounds healed with unprecedented speed, and new scar tissue was replaced with normal, healthy cells. An AIDS patient treated for Kaposi's sarcoma suddenly acquired new energy, appetite and an increasing T-cell count. Bacterial infections and even such parasites as tape worms and hook worms were found to disappear with IMI treatments, and new anecdotal reports of such coincidental cures and pain relief continue to come in from wherever the non-invasive IMI devices are used.
Such dramatic evidence of the safety and efficacy of the IMI quickly won officiai approval of its use in Greece, the European community and Canada. But puzzling questions remained as to how the IMI's short, powerful bursts of magnetic energy could effect such rapid healing and pain relief. In particular, there was the apparent paradox of how they could cause cancer cells and infectious organisms to die on the one hand, and renew vital energy to normal cells on the other. These mechanisms had to be reasonably explained before Professor Pappas' novel therapeutic device would be accepted by the medical and scientific community.
For this reason, he spent three years of sabbatical leave in the U.S. for the vast medical literature and research resources available here.
His constant and diligent eff orts succeeded in developing the evidence to support the explanations and theories presented below, which were used in applying for international patents on the IMI that have since been granted by many countries, including the U.S.A.
He also formed PAP ElectroDynamics USA, a California corporation to manufacture and market production models of the IMI for export and, after the anticipated U.S. Food and Drug Administration (FDA) approval is received, for the domestic market as well.
THE PAP IMI MODEL 600
The device produces a train of extremely short bursts of very high frequency oscillations by periodically exciting a gaseous plasma chamber at its natural resonant frequency.
Special precision circuitry limits each burst, or pulse of oscillations to :s 1 microsecond duration by a thyratron-type of control. The nanosecond rise and decay time of each pulse of oscillations is so steep that a wealth of thirdorder harmonics are generated in each pulse, which makes it difficult to characterize the resulting pulse frequency as other than an effectively narrow but complex frequency spectrum.
The remarkable aspect of this novel plasma-resonance method of generating such pulses of radio frequency energy is the extremely high amplitude (on the order of many kilovolts) they attain, resulting in massive current flow through the low-impedance load circuit. In this respect, and also by virtue of its complex frequency spectrum, the IMI is unique among the large family of Pulsed Electromagnetic Field (PEMF)'devices of which it is a member.
Also, unlike other PEMF devices that produce continuous trains of much wider and more closely-spaced, heat-generating pulses at MHz rates in a "woodpecker" effect, the pulse repetition frequency of the IMI is extremely low with relatively very long intervals between pulses. Variable control circuits limit the output pulses of the IMI to between two and five pulses per second at most therapeutic settings.
For this, and another reason connected with the manner in which the energy is delivered, the IMI has little or no heating effect on living tissue; it is considered to be an athermal PEMF device capable of delivering an effective and beneficial form of bioenergy to living cells.